Understanding how cancer cells resist cisplatin treatment and evade the immune system
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity
This study is looking at how some cancer cells change to survive treatment with cisplatin, a common chemotherapy drug, and aims to find ways to improve treatment by understanding these changes, which could help patients get better results from their therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10917409 on NIH RePORTER |
What this research studies
This research investigates how certain cancer cells adapt to survive treatment with cisplatin, a common chemotherapy drug. It focuses on the metabolic changes that occur in these cells, which allow them to resist therapy and suppress the immune response against tumors. By studying the energy production and metabolic pathways in resistant cancer cells, the researchers aim to identify potential targets for improving treatment outcomes. Patients may benefit from insights that could lead to new therapies that overcome resistance and enhance immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with head and neck squamous cell carcinoma (HNSCC) who have developed resistance to cisplatin treatment.
Not a fit: Patients with cancers that do not involve cisplatin treatment or those who have not received this chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with cisplatin-resistant cancers.
How similar studies have performed: Other research has shown success in understanding cancer cell metabolism and resistance mechanisms, indicating that this approach has potential for meaningful advancements.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Sandulache, Vlad C — University of Tx Md Anderson Can Ctr
- Study coordinator: Sandulache, Vlad C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.